Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.68 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.68 |
| ▸ | POLA1 | P09884 | 4/20 | 0.62 |
| ▸ | SOD1 | P00441 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26172616 | 1.00 | NR1H2 (0.68) | NR1H2NR1H3POLA1SOD1PTPN1 | |
| SCHEMBL29493613 | 1.00 | NR1H2 (0.68) | NR1H2NR1H3POLA1SOD1PTPN1 | |
| SCHEMBL23962236 | 1.00 | NR1H2 (0.68) | NR1H2NR1H3POLA1SOD1PTPN1 | |
| SCHEMBL6309781 | 0.93 | NR1H2 (0.69) | NR1H2NR1H3POLA1SOD1PTPN1 | |
| SCHEMBL6309780 | 0.93 | NR1H2 (0.69) | NR1H2NR1H3POLA1SOD1PTPN1 | |
| SCHEMBL6312187 | 0.91 | POLA1 (0.72) | NR1H2NR1H3POLA1PTPN1CYP2C9 | |
| SCHEMBL6312190 | 0.91 | POLA1 (0.72) | NR1H2NR1H3POLA1PTPN1CYP2C9 | |
| SCHEMBL20561120 | 0.91 | POLA1 (0.72) | NR1H2NR1H3POLA1PTPN1CYP2C9 | |
| SCHEMBL6309935 | 0.91 | POLA1 (0.72) | NR1H2NR1H3POLA1PTPN1CYP2C9 | |
| SCHEMBL6309929 | 0.91 | POLA1 (0.72) | NR1H2NR1H3POLA1PTPN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |